EG Capital Group

Presto is a hospitality technology company that overlays digital solutions onto the physical world to automate restaurant operations and enhance guest experiences. Its enterprise-grade voice, vision, and touch technologies support drive-thru automation, on-demand delivery management, and labor optimization for hospitality businesses. Having shipped over 250,000 systems, Presto ranks among the leading labor automation providers in the industry and serves major U.S. restaurant brands. Founded at MIT in 2008, the company is headquartered in Silicon Valley, California, and generates most of its revenue in the United States.

C4 Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapeutic candidates aimed at targeting and eliminating disease-causing proteins for the treatment of cancer, neurodegenerative diseases, and other conditions. The company's lead product candidate, CFT7455, is an orally bioavailable degrader targeting IKZF1/3, designed to treat multiple myeloma and various lymphomas. Additionally, C4 Therapeutics is advancing CFT8634, which targets BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors, as well as programs targeting BRAF V600E and RET for genetically defined resistant solid tumors. The company employs its proprietary Degronimid platform, which utilizes small molecule binders to flag harmful proteins for degradation by the cellular proteasome system, allowing for the potential treatment of previously undruggable targets. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics engages in strategic collaborations to enhance its research and development efforts.